Assessment of the current status of real-world pharmacogenomic testing : informed consent, patient education, and related practices
Copyright © 2024 Pereira, Haidar, Haga, Cisler, Hall, Shukla, Hebbring and Leary..
Introduction: The practice of informed consent (IC) for pharmacogenomic testing in clinical settings varies, and there is currently no consensus on which elements of IC to provide to patients. This study aims to assess current IC practices for pharmacogenomic testing. Methods: An online survey was developed and sent to health providers at institutions that offer clinical germline pharmacogenomic testing to assess current IC practices. Results: Forty-six completed surveys representing 43 clinical institutions offering pharmacogenomic testing were received. Thirty-two (74%) respondents obtain IC from patients with variability in elements incorporated. Results revealed that twenty-nine (67%) institutions discuss the benefits, description, and purpose of pharmacogenomic testing with patients. Less commonly discussed elements included methodology and accuracy of testing, and laboratory storage of samples. Discussion: IC practices varied widely among survey respondents. Most respondents desire the establishment of consensus IC recommendations from a trusted pharmacogenomics organization to help address these disparities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 15(2024) vom: 01., Seite 1355412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pereira, Lucas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical implementation |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2024.1355412 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369000994 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369000994 | ||
| 003 | DE-627 | ||
| 005 | 20240229235242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2024.1355412 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM369000994 | ||
| 035 | |a (NLM)38410134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pereira, Lucas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the current status of real-world pharmacogenomic testing |b informed consent, patient education, and related practices |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024 Pereira, Haidar, Haga, Cisler, Hall, Shukla, Hebbring and Leary. | ||
| 520 | |a Introduction: The practice of informed consent (IC) for pharmacogenomic testing in clinical settings varies, and there is currently no consensus on which elements of IC to provide to patients. This study aims to assess current IC practices for pharmacogenomic testing. Methods: An online survey was developed and sent to health providers at institutions that offer clinical germline pharmacogenomic testing to assess current IC practices. Results: Forty-six completed surveys representing 43 clinical institutions offering pharmacogenomic testing were received. Thirty-two (74%) respondents obtain IC from patients with variability in elements incorporated. Results revealed that twenty-nine (67%) institutions discuss the benefits, description, and purpose of pharmacogenomic testing with patients. Less commonly discussed elements included methodology and accuracy of testing, and laboratory storage of samples. Discussion: IC practices varied widely among survey respondents. Most respondents desire the establishment of consensus IC recommendations from a trusted pharmacogenomics organization to help address these disparities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical implementation | |
| 650 | 4 | |a genetic counseling | |
| 650 | 4 | |a genetic testing | |
| 650 | 4 | |a informed consent | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a pharmacogenomics | |
| 700 | 1 | |a Haidar, Cyrine-Eliana |e verfasserin |4 aut | |
| 700 | 1 | |a Haga, Susanne B |e verfasserin |4 aut | |
| 700 | 1 | |a Cisler, Anna G |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, April |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Sanjay K |e verfasserin |4 aut | |
| 700 | 1 | |a Hebbring, Scott J |e verfasserin |4 aut | |
| 700 | 1 | |a Leary, Emili J W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 15(2024) vom: 01., Seite 1355412 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:01 |g pages:1355412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2024.1355412 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 01 |h 1355412 | ||